These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 22183327)
1. Relieving bottlenecks in RNA drug discovery for retinal diseases. Sullivan JM; Yau EH; Taggart RT; Butler MC; Kolniak TA Adv Exp Med Biol; 2012; 723():145-53. PubMed ID: 22183327 [TBL] [Abstract][Full Text] [Related]
2. Eyes on systems pharmacology. Chen Y; Kern TS; Kiser PD; Palczewski K Pharmacol Res; 2016 Dec; 114():39-41. PubMed ID: 27720767 [No Abstract] [Full Text] [Related]
3. Zebrafish: a model system for the investigation of novel treatments for retinal disease. Gregory-Evans CY Adv Exp Med Biol; 2012; 723():399-405. PubMed ID: 22183358 [No Abstract] [Full Text] [Related]
4. A cellular high-throughput screening approach for therapeutic trans-cleaving ribozymes and RNAi against arbitrary mRNA disease targets. Yau EH; Butler MC; Sullivan JM Exp Eye Res; 2016 Oct; 151():236-55. PubMed ID: 27233447 [TBL] [Abstract][Full Text] [Related]
5. [Obstacles and approaches to the development of gene therapy and nucleic acid-based drug]. Shimizu K; Ando M Yakugaku Zasshi; 2012; 132(12):1371-2. PubMed ID: 23208043 [No Abstract] [Full Text] [Related]
6. Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma. Zhang K; Zhang L; Weinreb RN Nat Rev Drug Discov; 2012 Jun; 11(7):541-59. PubMed ID: 22699774 [TBL] [Abstract][Full Text] [Related]
7. Development of lead hammerhead ribozyme candidates against human rod opsin mRNA for retinal degeneration therapy. Abdelmaksoud HE; Yau EH; Zuker M; Sullivan JM Exp Eye Res; 2009 May; 88(5):859-79. PubMed ID: 19094986 [TBL] [Abstract][Full Text] [Related]
11. Development of ribozyme-based gene-inactivations; the example of the hepatitis delta virus ribozyme. Asif-Ullah M; Lévesque M; Robichaud G; Perreault JP Curr Gene Ther; 2007 Jun; 7(3):205-16. PubMed ID: 17584038 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic strategy for handling inherited retinal degenerations in a gene-independent manner using rod-derived cone viability factors. Léveillard T; Fridlich R; Clérin E; Aït-Ali N; Millet-Puel G; Jaillard C; Yang Y; Zack D; van-Dorsselaer A; Sahel JA C R Biol; 2014 Mar; 337(3):207-13. PubMed ID: 24702847 [TBL] [Abstract][Full Text] [Related]
13. What Is Next for Retinal Gene Therapy? Vandenberghe LH Cold Spring Harb Perspect Med; 2015 Apr; 5(10):. PubMed ID: 25877395 [TBL] [Abstract][Full Text] [Related]
15. Recent advances in genome editing of stem cells for drug discovery and therapeutic application. Lee J; Bayarsaikhan D; Bayarsaikhan G; Kim JS; Schwarzbach E; Lee B Pharmacol Ther; 2020 May; 209():107501. PubMed ID: 32061705 [TBL] [Abstract][Full Text] [Related]
16. Bottlenecks in development of retinal therapeutic post-transcriptional gene silencing agents. Sullivan JM; Yau EH; Taggart RT; Butler MC; Kolniak TA Vision Res; 2008 Feb; 48(3):453-69. PubMed ID: 17976683 [TBL] [Abstract][Full Text] [Related]
17. A chemogenetic approach to RNA function/structure analysis. Strobel SA Curr Opin Struct Biol; 1999 Jun; 9(3):346-52. PubMed ID: 10361087 [TBL] [Abstract][Full Text] [Related]
18. Gene therapy approaches for prevention of retinal degeneration in Usher syndrome. Williams DS; Chadha A; Hazim R; Gibbs D Gene Ther; 2017 Feb; 24(2):68-71. PubMed ID: 28054582 [No Abstract] [Full Text] [Related]
19. [What is the future of the genetic revolution in ophthalmology?]. Reichel MB Ophthalmologe; 2002 Apr; 99(4):257-8. PubMed ID: 12058499 [No Abstract] [Full Text] [Related]
20. [Gene editing in drug discovery and therapeutic innovation]. Galzi JL Med Sci (Paris); 2019 Apr; 35(4):309-315. PubMed ID: 31038108 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]